Author is bullish on Novo Nordisk after the 25 mg Wegovy pill FDA approval and is holding until at least $90.
NVO — LONG The author is bullish on Novo Nordisk following FDA approval of the 25 mg oral Wegovy pill launched at $299/month. They argue the product is a few months ahead of similar competing products and could capture significant market share. The author is waiting for February earnings and forecasts for confirmation and is holding until at least $90.
Being a few months ahead of other similar products, can this capture a significant market share and how will revenue grow after all the repricing taken place lately? Waiting for February earnings and forecasts to have a clear view. Holding until at least $90.
This Reddit post, published January 05, 2026, features u/Aniriomellad discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Aniriomellad · Tickers: NVO